References
- Trillet-Lenoir V, Green J A, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319–324
- Lieschke G J, Burgess A W. Granulocyte colony-stimulating factor and granuloctye-macrophage colony-stimulating factor. N Engl J Med 1992; 327: 99–106
- British Committee for Standards in Haematology, Milligan D W, Grimwade D, Cullis J O, Bond L, Swirsky D, et al. Guidelines on the management of acute myeloid leukemia in adults. Br J Haematol 2006; 135: 450–474
- Löwenberg B, van Putten W, Theobald M, Gmür J, Verdonck L, Sonneveld P, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743–752
- Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, et al. A controlled study of recombininat human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogrnous leukemia. N Engl J Med 1995; 332: 1678–1683
- Xavier L, Cunha M, Gonçalves C, Teixeira M A, Coutinho J, Ribeiro A C, et al. Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy. Leuk Lymphoma 2003; 44: 2137–2142
- Heil G, Hoelzer D, Sanz M A, Lechner K, Liu Y JA, Papa G, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710–4718
- Bradstock K, Matthews J, Young G, Lowenthal R, Baxter H, Arthur C, et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukemia. Leukemia 2001; 15: 1331–1338
- Goldstone A H, Burnett A K, Wheatley K, Smith A G, Hutchinson R M, Clark R E, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302–1311
- Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N, et al. Efficacy of granulocyte colony-stimulating factor in thetreatment of acute myelogenous leukemia: a multicentre randomized study. Br J Haematol 2002; 116: 103–112
- Godwin J E, Kopecky K J, Head D R, Willman C L, Leith C P, Hynes H E, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a southwest oncology group study (9031). Blood 1998; 91: 3607–3615
- Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie J P, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27–34
- Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer C M, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499–4506
- van Tulder M, Furlan A, Bombardier C, Bouter L, Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine 2003; 28: 1290–1299
- Berlin J A, Laird N M, Sacks H S, Chalmers T C. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989; 8: 141–151